Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society–USA Panel
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
CONTEXT: The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral-naive and -experienced patients warrant an update of the International AIDS Society-USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus (HIV) infection. OBJECTIVES: To summarize new data in the field and to provide current recommendations for the antiretroviral management and laboratory monitoring of HIV infection. This report provides guidelines in key areas of antiretroviral management: when to initiate therapy, choice of initial regimens, patient monitoring, when to change therapy, and how best to approach treatment options, including optimal use of recently approved drugs (maraviroc, raltegravir, and etravirine) in treatment-experienced patients. DATA SOURCES AND STUDY SELECTION: A 14-member panel with expertise in HIV research and clinical care was appointed. Data published or presented at selected scientific conferences since the last panel report (August 2006) through June 2008 were identified. DATA EXTRACTION AND SYNTHESIS: Data that changed the previous guidelines were reviewed by the panel (according to section). Guidelines were drafted by section writing committees and were then reviewed and edited by the entire panel. Recommendations were made by panel consensus. CONCLUSIONS: New data and considerations support initiating therapy before CD4 cell count declines to less than 350/microL. In patients with 350 CD4 cells/microL or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non-AIDS diseases, and patient readiness for treatment. In addition to the prior recommendation that a high plasma viral load (eg, >100,000 copies/mL) and rapidly declining CD4 cell count (>100/microL per year) should prompt treatment initiation, active hepatitis B or C virus coinfection, cardiovascular disease risk, and HIV-associated nephropathy increasingly prompt earlier therapy. The initial regimen must be individualized, particularly in the presence of comorbid conditions, but usually will include efavirenz or a ritonavir-boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine). Treatment failure should be identified and managed promptly, with the goal of therapy, even in heavily pretreated patients, being an HIV-1 RNA level below assay detection limits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationGrulich, A. E., van Leeuwen, M. T., Falster, M. O., & Vajdic, C. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61050-2 · Cited by 2,323
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Sexually transmitted disease surveillance.
Schofield, C. B. (1982) · BMJ · doi:10.1136/bmj.284.6318.825-c · Cited by 1,869
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Self-citationPalella, F. J., Baker, R. K., Moorman, A. C., Chmiel, J. S., Wood, K. C., Brooks, J. T., & Holmberg, S. D. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233310.90484.16 · Cited by 1,350
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.033 · Cited by 1,075
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationAttia, S., Egger, M., Müller, M., Zwahlen, M., & Low, N. (2009) · AIDS · doi:10.1097/qad.0b013e32832b7dca · Cited by 1,001
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., et al. (1998) · JAMA · doi:10.1001/jama.280.1.78 · Cited by 995
Self-citationPatel, P., Hanson, D. L., Sullivan, P. S., Novak, R. M., Moorman, A. C., Tong, T. C., Holmberg, S. D., Brooks, J. T., & for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-10-200805200-00005 · Cited by 942
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Self-citationTreatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Self-citationDanesh, J., Kaptoge, S., Mann, A. G., Sarwar, N., Wood, A., Angleman, S. B., Wensley, F., Higgins, J. P. T., Lennon, L., Eiriksdottir, G., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050078 · Cited by 676
HIV-1 Transmission, by Stage of Infection
Hollingsworth, T. D., Anderson, R. M., & Fraser, C. (2008) · The Journal of Infectious Diseases · doi:10.1086/590501 · Cited by 652
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
Self-citationGupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Zolopa, A. R., Andersen, J., Komarow, L., Sanne, I., Sanchez, A., Hogg, E., Suckow, C., Powderly, W., & for the ACTG A5164 study team (2009) · PLoS ONE · doi:10.1371/journal.pone.0005575 · Cited by 567
Carpenter, C. C. J. (1996) · JAMA · doi:10.1001/jama.276.2.146 · Cited by 541
Qurishi, N., Kreuzberg, C., Lüchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., Rockstroh, J. K., & Spengler, U. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14844-1 · Cited by 525
Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61047-2 · Cited by 517
Self-citationMolina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients
De Wit, S., Sabin, C. A., Weber, R., Worm, S. W., Reiss, P., Cazanave, C., El-Sadr, W., Monforte, A. D., Fontas, E., Law, M. G., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2013 · Cited by 482
Self-citationPalella, F. J., Deloria-Knoll, M., Chmiel, J. S., Moorman, A. C., Wood, K. C., Greenberg, A. E., Holmberg, S. D., & and the HIV Outpatient Study (HOPS) Investigators* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00007 · Cited by 443
Moore, R. D., & Keruly, J. C. (2007) · Clinical Infectious Diseases · doi:10.1086/510746 · Cited by 415
Markowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
Lewden, C., Chêne, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., Pellegrin, J.-L., Katlama, C., Dabis, F., & Leport, C. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318134257a · Cited by 402
Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV
Castilla, J., del Romero, J., Hernando, V., Marincovich, B., García, S., & Rodríguez, C. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000157389.78374.45 · Cited by 384
Markowitz, M., Morales-Ramirez, J. O., Nguyen, B.-Y., Kovacs, C. M., Steigbigel, R. T., Cooper, D. A., Liporace, R., Schwartz, R., Isaacs, R., Gilde, L. R., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31802b4956 · Cited by 368
Eron, J., Yeni, P., Gathe, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P., Katlama, C., Young, B., Yau, L., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69155-1 · Cited by 344
Self-citationMadruga, J. V., Berger, D., McMurchie, M., Suter, F., Banhegyi, D., Ruxrungtham, K., Norris, D., Lefebvre, E., de Béthune, M.-P., Tomaka, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61049-6 · Cited by 336
Nephropathy and Establishment of a Renal Reservoir of HIV Type 1 during Primary Infection
Winston, J. A., Bruggeman, L. A., Ross, M. D., Jacobson, J., Ross, L., D'Agati, V. D., Klotman, P. E., & Klotman, M. E. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442604 · Cited by 315
Martin, A., Smith, D. E., Carr, A., Ringland, C., Amin, J., Emery, S., Hoy, J., Workman, C., Doong, N., Freund, J., et al. (2004) · AIDS · doi:10.1097/00002030-200404300-00011 · Cited by 297
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., & Mallal, S. (2006) · Clinical Infectious Diseases · doi:10.1086/504874 · Cited by 296
The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067710 · Cited by 292
Lucas, G. M., Eustace, J. A., Sozio, S., Mentari, E. K., Appiah, K. A., & Moore, R. D. (2004) · AIDS · doi:10.1097/00002030-200402200-00022 · Cited by 268
Mills, A., Nelson, M. R., Jayaweera, D. T., Ruxrungtham, K., Cassetti, I., Girard, P., Workman, C., Dierynck, I., Sekar, V. J., Abeele, C. V., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832d7350 · Cited by 268
Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis
Parienti, J., Bangsberg, D. R., Verdon, R., & Gardner, E. M. (2009) · Clinical Infectious Diseases · doi:10.1086/596482 · Cited by 244
Predictors of proteinuria and renal failure among women with HIV infection
Szczech, L. A., Gange, S. J., van der Horst, C., Bartlett, J. A., Young, M., Cohen, M. H., Anastos, K., Klassen, P. S., & Svetkey, L. P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00094.x · Cited by 241
Arribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Holmes, C. B., Enejosa, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acab8 · Cited by 235
Nikolopoulos, G. K., Paraskevis, D., Hatzitheodorou, E., Moschidis, Z., Sypsa, V., Zavitsanos, X., Kalapothaki, V., & Hatzakis, A. (2009) · Clinical Infectious Diseases · doi:10.1086/599110 · Cited by 231
L??pez-Cort??s, L. F., Ruiz-Valderas, R., Viciana, P., Alarc??n-Gonz??lez, A., G??mez-Mateos, J., Le??n-Jimenez, E., Sarasanacenta, M., L??pez-Pua, Y., & Pach??n, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00004 · Cited by 229
Gulick, R. M. (2006) · JAMA · doi:10.1001/jama.296.7.769 · Cited by 219
Kempf, D. J., King, M. S., Bernstein, B., Cernohous, P., Bauer, E., Moseley, J., Gu, K., Hsu, A., Brun, S., & Sun, E. (2004) · The Journal of Infectious Diseases · doi:10.1086/380509 · Cited by 217
Smith, K. Y., Patel, P., Fine, D., Bellos, N., Sloan, L., Lackey, P., Kumar, P. N., Sutherland-Phillips, D. H., Vavro, C., Yau, L., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832cbcc2 · Cited by 217
Antiretroviral drugs and liver injury
Soriano, V., Puoti, M., Garcia-Gascó, P., Rockstroh, J. K., Benhamou, Y., Barreiro, P., & McGovern, B. (2008) · AIDS · doi:10.1097/qad.0b013e3282f0e2fd · Cited by 216
Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00534.x · Cited by 210
Self-citationBoulle, A. (2008) · JAMA · doi:10.1001/jama.300.5.530 · Cited by 201
Malan, D. R., Krantz, E., David, N., Wirtz, V., Hammond, J., & McGrath, D. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815ace6a · Cited by 147
Grade 4 Events Are as Important as AIDS Events in the Era of HAART
Reisler, R. B., Han, C., Burman, W. J., Tedaldi, E., & Neaton, J. D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00004 · Cited by 147
Moyle, G. J., Baldwin, C., Langroudi, B., Mandalia, S., & Gazzard, B. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200305010-00004 · Cited by 128
Racial Differences in End-Stage Renal Disease Rates in HIV Infection versus Diabetes
Choi, A. I., Rodriguez, R. A., Bacchetti, P., Bertenthal, D., Volberding, P. A., & O'Hare, A. M. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040402 · Cited by 122
Self-citationFriedland, G. H., Khoo, S., Jack, C., & Lalloo, U. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl399 · Cited by 120
Parsonage, M., Wilkins, E., Snowden, N., Issa, B., & Savage, M. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00318.x · Cited by 119
Lau, B. M., Gange, S. J., & Moore, R. D. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000247229.68246.c5 · Cited by 119
Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients
Gupta, S. K., Mamlin, B. W., Johnson, C. S., Dollins, M. D., Topf, J. M., & Dubé, M. P. (2004) · Clinical Nephrology · doi:10.5414/cnp61001 · Cited by 115
Opravil, M., Ledergerber, B., Furrer, H., Hirschel, B. J., Imhof, A., Gallant, S., Wagels, T., Bernasconi, E., Meienberg, F., Rickenbach, M., et al. (2002) · AIDS · doi:10.1097/00002030-200207050-00009 · Cited by 111
Cameron, D. W., da Silva, B. A., Arribas, J. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/589622 · Cited by 111
Protease inhibitors are associated with a slowed progression of HIV-related renal diseases
Szczech, L. A., Edwards, L. J., Sanders, L. L., van der Horst, C., Bartlett, J. A., Heald, A. E., & Svetkey, L. P. (2002) · Clinical Nephrology · doi:10.5414/cnp57336 · Cited by 103
Boulanger, C., Hollender, E. S., Farrell, K., Stambaugh, J. J., Maasen, D., Ashkin, D., Symes, S. N., Espinoza, L. A., Rivero, R. O., Graham, J. J., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/606056 · Cited by 100
The UK Collaborative HIV Cohort Study Steering Committee (2007) · AIDS · doi:10.1097/qad.0b013e32827038bf · Cited by 94
Sterling, T. R., Chaisson, R. E., Keruly, J. C., & Moore, R. D. (2003) · The Journal of Infectious Diseases · doi:10.1086/379741 · Cited by 92
Lichtenstein, K. A., Armon, C., Buchacz, K. A., Chmiel, J. S., Moorman, A. C., Wood, K. C., Holmberg, S. D., & Brooks, J. T. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acacc · Cited by 77
When should antiretroviral therapy for HIV be started?
Phillips, A. N., Gazzard, B., Clumeck, N., Losso, M. H., & Lundgren, J. D. (2007) · BMJ · doi:10.1136/bmj.39064.406389.94 · Cited by 74
Jaén, Á., Esteve, A., Miró, J. M., Tural, C., Montoliu, A., Ferrer, E., Riera, M., Segura, F., Force, L., Sued, O. G., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815ee282 · Cited by 68
Self-citationDubé, M. P., Komarow, L., Mulligan, K. M., Grinspoon, S. K., Parker, R. A., Robbins, G. K., Roubenoff, R., & Tebas, P. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181142d26 · Cited by 66
Kaplan, J. E., Hanson, D. L., Cohn, D. L., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/377606 · Cited by 51
Ward, D. J., & Curtin, J. (2006) · AIDS Patient Care and STDs · doi:10.1089/apc.2006.20.542 · Cited by 50
Moyle, G. J., Higgs, C. J., Teague, A., Mandalia, S., Nelson, M. R., Johnson, M. A., Fisher, M., & Gazzard, B. (2006) · Antiviral Therapy · doi:10.1177/135965350601100106 · Cited by 43
Jenny-Avital, E. R., & Joseph, K. (2009) · Clinical Infectious Diseases · doi:10.1086/598336 · Cited by 43
Luber, A., Brower, R., Kim, D., Silverman, R., Peloquin, C. A., & Frank, I. (2007) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00496.x · Cited by 34
von Hentig, N., Koenigs, C., Elanjikal, S., et al. (2006) · PubMed · Cited by 29
Wood, E., Hogg, R. S., Yip, B., Moore, D. M., Harrigan, P. R., & Montaner, J. (2007) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00430.x · Cited by 19
Self-citationDesign Issues in Initial HIV-Treatment Trials: Focus on Actg A5095
Ribaudo, H. J., Kuritzkes, D. R., Schackman, B. R., Acosta, E. P., Shikuma, C. M., & Gulick, R. M. (2006) · Antiviral Therapy · doi:10.1177/135965350601100605 · Cited by 15
Risk of myocardial infarction and nucleoside analogues
Stein, J. H., & Currier, J. S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60491-2 · Cited by 13
Neaton, J. D., & Grund, B. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282f3808b · Cited by 11
Hill, A. M., Miralles, D., Vangeneugden, T., & Lefebvre, E. A. (2007) · AIDS · doi:10.1097/qad.0b013e3282703593 · Cited by 10
Walmsley, S. L., Cotte, L., Rusconi, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3282ef6db7 · Cited by 10
Self-citationLodwick, R. K., Porter, K. R., Sabin, C. A., Ledergerber, B., Cozzi‐Lepri, A., Khaykin, P., Mocroft, A., Jacobson, L. A., Wit, S. D., & Phillips, A. N. (2008) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 8
Cited by
Samji, H., Cescon, A., Hogg, R. S., Modur, S. P., Althoff, K. N., Buchacz, K., Burchell, A. N., Cohen, M., Gebo, K. A., Gill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081355 · Cited by 1,417
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Self-citationPolymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Das, M., Chu, P. L., Santos, G.-M., Scheer, S., Vittinghoff, E., McFarland, W., & Colfax, G. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011068 · Cited by 771
Metadata
- Authors
- Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., Jacobsen, D. M., Montaner, J. S. G., Richman, D. D., Yeni, P. G., & Volberding, P. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-08-06
- Volume
- 300
- Issue
- 5
- Pages
- 555
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2182777591
- Cited by
- 1,026
- References
- 87
- FWCI
- 126.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.